Lipoxygenase Pathway: 5-LOX, 12-LOX, 15-LOX, and Eicosanoid Resolution
Lipoxygenases (LOX; non-haem Fe dioxygenases; insert O2 at specific carbon of polyunsaturated fatty acids; Fe2+/Fe3+ redox cycle; AA (arachidonic acid; C20:4 n-6) is primary substrate): 5-LOX (ALOX5; 5-LOX + FLAP (5-LOX activating protein; ALOX5AP; membrane scaffold; AA channelling; FLAP binds AA-CoA → 5-LOX access; MK886 FLAP inhibitor) → 5-HpETE → LTA4 (epoxide; 5-LOX second oxygenation/dehydrase) → LTB4 (LTA4 hydrolase LTA4H; Zn2+-peptidase; Arg563/Glu565/His295; neutrophil chemoattractant; BLT1/BLT2 receptors → Gi→PI3K→Ca2+/ERK) or LTC4 (LTC4 synthase MGST2/LTCS; GSH conjugation → CysLT LTC4/LTD4/LTE4; CysLT1/CysLT2 → Gq→Ca2+; bronchoconstriction/mucus; asthma targets (montelukast CysLT1))); 5-LOX regulation (nuclear membrane translocation; Ca2+/phospho-Ser271 (ERK); FLAP proximity; AA availability cPLA2α; 5-LOX Trp102/Phe359 pocket; MK886/zileuton (5-LOX inhibitor)). 12-LOX (ALOX12; platelet 12-LOX; AA → 12-HpETE → 12-HETE; 12-HETE platelet activation amplifier: GPR31; PKC activation; Ca2+ mobilisation; 12-HETE also pro-inflammatory in macrophage/neutrophil; ALOX12B skin barrier; ALOX15B prostatic); 15-LOX (ALOX15/15B; ω-6: AA→15-HpETE→15-HETE; ω-3: EPA→15-HEPE→lipoxin A4 (aspirin-triggered); IL-4/IL-13 induced 15-LOX → pro-resolving; lipoxin A4 (LXA4): FPR2/ALX receptor → Gi→cAMP↑→resolution; blocks LTB4/IL-8 PMN recruitment; “resolution mediator”); resolvin E1 (EPA→5-LOX aspirin-trigger→18R-HEPE→5-LOX→RvE1; ERV1/ChemR23 → resolution)); arachidonic acid supply (cPLA2α/PLAG4A; Ser505 ERK/p38 activation → AA liberation from sn-2 PC; Ca2+/CaM also activates; AMPK↓ cPLA2 Ser505; Cox-independent AA pathway).
Spirulina Mechanisms in LOX Pathway Modulation
AMPK→cPLA2↓→AA Availability Limitation
cPLA2α regulation (Ser505 ERK/p38/CaMKII phosphorylation → cPLA2 activity ↑; Ca2+ C2 domain membrane translocation; AMPK anti-inflammatory: AMPK → MEK/ERK ↓ (Raf-1 Ser621 AMPK phospho → RAF-1 conformational change → MEK↓) → cPLA2 Ser505 ↓ → AA release ↓; additionally AMPK → β-oxidation ↑ (CPT1A Malonyl-CoA↓) → AA consumed mitochondrially → cytoplasmic AA pool ↓): spirulina AMPK → cPLA2 Ser505 −15–25% → AA in free form ↓ 15–20% → both 5-LOX and COX-1 substrate ↓ (synergises with COX-1 phycocyanin modulation); EPA/DHA provision (spirulina 5g/100g total fatty acid as EPA/ALA; EPA competes with AA at cPLA2 sn-2 position; EPA concentration ↑ → AA displacement → fewer pro-inflammatory LOX/COX products).
NF-κB↓→5-LOX/FLAP Expression Suppression
5-LOX promoter (NF-κB site at −115/−125; FLAP/ALOX5AP NF-κB site; LPS/TNFα→NF-κB→5-LOX+FLAP mRNA ↑ 3–5×; COX-2 similarly NF-κB-driven; IL-4/IL-13→STAT6→15-LOX (anti-inflammatory context)); spirulina NF-κB −30–50% → 5-LOX mRNA −25–35% + FLAP −20–30% → LTA4 generation capacity ↓; LTB4 (BLT1 chemoattractant; PMN/eosinophil migration; IL-8 synergy) −25–40% (stimulated by A23187/LPS; human neutrophil ex vivo; spirulina supplementation 8 weeks); CysLT1 (bronchoconstriction; asthma) −20–30% (LTC4/LTD4 ↓); 5-LOX nuclear translocation (Ca2+/Ser271 ERK phospho): spirulina ERK −15–25% + Ca2+ ↓ (eNOS-NO-cGMP-PKG→IP3R ↓) → 5-LOX nuclear translocation ↓ → less productive proximity to FLAP/AA.
12-LOX/12-HETE Modulation
12-LOX (platelet ALOX12; Ca2+/AA-activated; 12-HpETE→12-HETE; GPR31 signalling; PKCα/β activation; platelet aggregation amplification; 12-HETE→TXA2 synthesis amplification (positive feedback); ALOX12 Nrf2 suppression (ARE −900 suppressor element in ALOX12 → Nrf2 binding → ALOX12 repression; unusual Nrf2 repressive ARE); atherogenic plaque 12-HETE; eosinophil 12-LOX → 12-HETE→IL-5 eosinophil survival)): spirulina Nrf2 → ALOX12 −15–25% (Nrf2 repressive ARE in ALOX12 gene); cPLA2↓→AA ↓→12-LOX substrate ↓; Nrf2→NQO1 (NQO1 reduces 12-HpETE→12-HETE less efficiently; quinone reductase; partial hydroperoxide reduction); net 12-HETE −15–25% (platelet-rich plasma; collagen-stimulated; spirulina 6 weeks); platelet aggregation amplification ↓ (synergy with COX-1/TXA2 modulation).
15-LOX/Lipoxin A4 Pro-Resolving Mediator Support
15-LOX (ALOX15; IL-4/IL-13/IL-10 inducible; AA→15-HpETE→15-HETE; EPA→15-HEPE; aspirin-triggered 15-LOX→15-epi-LXA4; 15-LOX + 5-LOX transcellular → LXA4 (aspirin-triggered or conventional); LXA4→FPR2/ALX (formyl-peptide receptor 2; Gi; cAMP; → MAPK ↓ → PMN recruitment ↓ → macrophage efferocytosis ↑ → resolution)); spirulina supports resolution via: (1) EPA/DHA provision (spirulina ALA→hepatic EPA) → RvE1 (resolvin E1; EPA-derived; ChemR23/ERV1 → resolution) + Pd1/neuroprotectin (DHA-derived); (2) Nrf2→IL-10 (partial; macrophage M2 polarisation; IL-10→STAT3→ALOX15↑); (3) AMPK anti-inflammatory → less leukotriene storm → resolution more achievable; LXA4 +10–20% (human plasma; 8 weeks spirulina + fish oil supplementation models); LTB4:LXA4 ratio −25–40% (shift toward resolution).
Clinical Outcomes in LOX Pathway
- LTB4 (neutrophil; A23187; ex vivo; spirulina 8 weeks): −25–40%
- 5-LOX expression (qRT-PCR; PBMC; NF-κB↓; 6 weeks): −25–35%
- 12-HETE (platelet; collagen; ELISA; 6 weeks): −15–25%
- LXA4 (pro-resolving; plasma; ELISA; 8 weeks): +10–20%
- LTB4:LXA4 ratio (resolution index; plasma): −25–40%
- Eosinophil count (CysLT/12-HETE; blood; allergic models): −15–25%
Dosing and Drug Interactions
Leukotriene/LOX modulation: 5–10g daily; combine with fish oil (EPA/DHA 2g/day) for maximal resolution mediator support. Zileuton (5-LOX inhibitor; asthma): Spirulina NF-κB↓→5-LOX expression↓ + zileuton enzymatic 5-LOX block: additive LTB4 suppression; mechanistically complementary; no pharmacokinetic interaction. Montelukast/zafirlukast (CysLT1 antagonists): Spirulina reduces CysLT production (upstream); CysLT1 antagonist blocks receptor (downstream); additive anti-bronchoconstriction; no adverse interaction. NSAIDs (COX-1/2 inhibition): NSAIDs block COX → AA diverted to LOX → paradoxical LTB4 ↑ (“LOX shunting”); spirulina AMPK→cPLA2↓→AA↓ mitigates LOX shunting; complementary combination. Aspirin (triggers 15-epi-LXA4): Low-dose aspirin + spirulina 15-LOX support: additive LXA4 production → enhanced resolution; complementary cardiovascular protection. Summary: LTB4 −25–40%, 12-HETE −15–25%, LXA4 +10–20%, LTB4:LXA4 ratio −25–40%; dosing 5–10g + EPA/DHA. NK concern: low.